The two products will be used in Opus Genetics’ research into inherited retinal disease, specifically bestrophin-1 and rhodopsin-mediated autosomal dominant retinitis pigmentosa, according to a Dec. 28 news release.
In exchange for the two products, Iveric Bio received $500,000 and “high single-digit percentage ownership of Opus,” according to the release. The company is also eligible for development and regulatory milestone payments, sales milestone payments, and a low single-digit earnout on net sales of the products. Iveric will retain certain rights with respect to the potential future commercialization of gene therapy products for BEST1 and/or RHO -adRP.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
